IMVT

Immunovant, Inc.

36.17 USD
-0.33 (-0.90%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Immunovant, Inc. stock is down -8.1% since 30 days ago. The next earnings date is May 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 4 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 4 CALLs, 6 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
11 Jan 18:23 19 Jan, 2024 7.50 CALL 13 1548
19 Jan 16:01 16 Feb, 2024 50.00 CALL 400 48
24 Jan 15:19 19 Apr, 2024 35.00 PUT 198 506
29 Jan 14:35 17 Jan, 2025 40.00 CALL 316 197
29 Jan 14:35 17 Jan, 2025 40.00 CALL 84 197
30 Jan 20:22 19 Jul, 2024 40.00 PUT 53 40
02 Feb 14:59 02 Feb, 2024 38.00 PUT 100 136
02 Feb 17:24 02 Feb, 2024 37.00 PUT 200 200
02 Feb 18:43 19 Apr, 2024 35.00 PUT 200 728
20 Feb 16:48 23 Feb, 2024 36.00 PUT 1847 10

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.

  • JP Morgan
    Tue Feb 20, 06:30
    buy
    initial
  • Wolfe Research
    Thu Feb 15, 06:38
    buy
    initial